HRP20171898T1 - Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika - Google Patents
Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika Download PDFInfo
- Publication number
- HRP20171898T1 HRP20171898T1 HRP20171898TT HRP20171898T HRP20171898T1 HR P20171898 T1 HRP20171898 T1 HR P20171898T1 HR P20171898T T HRP20171898T T HR P20171898TT HR P20171898 T HRP20171898 T HR P20171898T HR P20171898 T1 HRP20171898 T1 HR P20171898T1
- Authority
- HR
- Croatia
- Prior art keywords
- ribavirin
- combination
- daas
- patient
- use according
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims 19
- 229960000329 ribavirin Drugs 0.000 title claims 19
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims 19
- 239000003443 antiviral agent Substances 0.000 title claims 2
- 238000011282 treatment Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000134307 Hepatitis C virus genotype 1 Species 0.000 claims 1
- 241000122128 Hepatitis C virus genotype 2 Species 0.000 claims 1
- 241001093325 Hepatitis C virus genotype 3 Species 0.000 claims 1
- 241001466980 Hepatitis C virus genotype 4 Species 0.000 claims 1
- 241001466982 Hepatitis C virus genotype 5 Species 0.000 claims 1
- 241000143279 Hepatitis C virus genotype 6 Species 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Kombinacija najmanje dva antivirusna sredstva koja djeluju izravno (DAA) i ribavirina za uporabu u postupku liječenja infekcije virusom hepatitisa C, pri čemu navedeni postupak uključuje davanje navedene kombinacije najmanje dva DAA i ribavirina pacijentu s hepatitisom C, naznačena time da navedeno liječenje ne uključuje primjenu interferona na navedenog pacijenta, a navedeno liječenje traje 8, 9, 10, 11, 12 ili 16 tjedana, te pri čemu navedena barem dva DAA sadrže:
[image]
ili njegovu farmaceutski prihvatljivu sol, i
[image]
2. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema zahtjevu 1, naznačena time da navedeno liječenje traje 12 tjedana.
3. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema zahtjevu 1, naznačena time da navedeno liječenje traje 8 tjedana.
4. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 1 virusa hepatitisa C.
5. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 1a virusa hepatitisa C.
6. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 2 virusa hepatitisa C.
7. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 3 virusa hepatitisa C.
8. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 4 virusa hepatitisa C.
9. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 5 virusa hepatitisa C.
10. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da je navedeni pacijent inficiran s genotipom 6 virusa hepatitisa C.
11. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da navedeni pacijent je bez ciroze.
12. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da navedeni pacijent je s kompenziranom cirozom.
13. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da navedeni pacijent je pacijent koji nije liječen.
14. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da navedeni pacijent je pacijent koji ne odgovara na liječenje interferonom.
15. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-3, naznačena time da navedeni pacijent je pacijent koji se dugotrajno liječi.
16. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-15, naznačena time da se navedena najmanje dva DAA sastoje od (1) Spoja 1 njegove farmaceutski prihvatljive soli i (2) Spoja 2 njegove farmaceutski prihvatljive soli.
17. Kombinacija najmanje dva DAA i ribavirina za upotrebu prema bilo kojem od zahtjeva 1-16, naznačena time da se Spoj 1 ili njegova farmaceutski prihvatljiva sol, i Spoj 2 ili njegova farmaceutski prihvatljiva sol, primjenjuju jednom dnevno na navedenog pacijenta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| EP14725812.3A EP2968302B9 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171898T1 true HRP20171898T1 (hr) | 2018-04-06 |
Family
ID=50771575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171898TT HRP20171898T1 (hr) | 2013-03-14 | 2017-12-06 | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (hr) |
| EP (4) | EP3915559A1 (hr) |
| JP (3) | JP6563894B2 (hr) |
| KR (2) | KR20180045055A (hr) |
| CN (3) | CN109908353A (hr) |
| AU (3) | AU2014239322B2 (hr) |
| BR (1) | BR112015020918A2 (hr) |
| CA (1) | CA2901818C (hr) |
| CY (1) | CY1121474T1 (hr) |
| DK (1) | DK2968302T3 (hr) |
| EA (2) | EA201890507A1 (hr) |
| ES (1) | ES2654109T3 (hr) |
| HK (2) | HK1213191A1 (hr) |
| HR (1) | HRP20171898T1 (hr) |
| HU (1) | HUE036069T2 (hr) |
| IL (2) | IL240445B (hr) |
| LT (1) | LT2968302T (hr) |
| MX (1) | MX2015012536A (hr) |
| NO (1) | NO3090119T3 (hr) |
| PL (1) | PL2968302T3 (hr) |
| PT (1) | PT2968302T (hr) |
| RS (1) | RS56735B1 (hr) |
| SG (2) | SG11201507361YA (hr) |
| SI (1) | SI2968302T1 (hr) |
| TW (2) | TW202002979A (hr) |
| WO (1) | WO2014152635A1 (hr) |
| ZA (1) | ZA201705080B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456621A (zh) * | 2013-03-14 | 2017-02-22 | 艾伯维公司 | 用于治疗hcv的方法 |
| SI2968302T1 (en) * | 2013-03-14 | 2018-04-30 | Abb Vie Inc. | Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| MX2016005393A (es) * | 2013-10-25 | 2016-08-11 | Abbvie Inc | Metodos para tratar vhc. |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| ES2825373T3 (es) | 2016-01-08 | 2021-05-17 | Entrust Datacard Corp | Mecanismo de impresión de tarjetas con trayectoria de retorno de tarjetas |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CA3037719A1 (en) * | 2016-09-23 | 2018-03-29 | Abbvie Inc. | Dose adjustment |
| CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| EP3773753A4 (en) * | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010013522A (es) * | 2008-06-10 | 2011-05-03 | Janssen Pharmaceutica Nv | Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c. |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| DK2455376T3 (en) * | 2009-06-11 | 2015-03-02 | Abbvie Bahamas Ltd | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) |
| NZ608720A (en) | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| ES2527544T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC |
| SI2968302T1 (en) | 2013-03-14 | 2018-04-30 | Abb Vie Inc. | Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV |
-
2014
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko active IP Right Grant
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en active Application Filing
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko active IP Right Grant
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 PL PL14725812T patent/PL2968302T3/pl unknown
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2016
- 2016-02-02 HK HK16101220.2A patent/HK1213191A1/zh not_active IP Right Cessation
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/zh unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| HRP20171036T1 (hr) | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c | |
| JP2014530874A5 (hr) | ||
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| JP2016513703A5 (hr) | ||
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| HRP20110713T1 (hr) | Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830 | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| RU2013105504A (ru) | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы | |
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
| EA201491652A1 (ru) | Средство для лечения вирусного гепатита с | |
| RU2014116988A (ru) | Алиспоривир для лечения инфекции, вызванной вирусом гепатита с | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| WO2014140680A8 (en) | Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection | |
| MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
| MX2016002856A (es) | Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon. |